Press release
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT
About this update from Insmed Incorporated
[{"type":"text","content":"—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session—\n—New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic Fibrosis Bronchiectasis by Reduction of Exacerbation History— \nBRIDGEWATER, N.J., Sept. 22, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present seven abstracts from across its late-stage portfolio at the European Respiratory Society (ERS) 2025 Congress, taking place September 27 – October 1, 2025, in Amsterdam.\nNotably, data from the Phase 2 trial in treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) will be highlighted in the Congress's Abstracts Leading to Evolution in Respiratory Medicine Trials (ALERT) session, which showcases important, late-breaking clinical data from all respiratory disease areas. In addition, presentations include three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating the efficacy and safety of brensocatib, including Japanese patient data, as well as Health Outcomes and Economic Research from The Health Improvement Network® (THIN) database in France and the United Kingdom in patients with non-cystic fibrosis bronchiectasis (NCFB).\n\"Our deep commitment to transforming care in serious respiratory and pulmonary diseases is evident in the recognition of our TPIP Phase 2b study in PAH as part of the prestigious ALERT session, along with the presentation of multiple analyses for brensocatib,\" said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. \"We are eager to showcase the strength and breadth of our data and the potential impact it may have for patients and the clinical community.\"\nPresentations:\nOral Presentation Elicium 1, Sunday, September 28, 15:50 – 15:55 PM CESTPresenting Author: Michael LoebingerEfficacy and Safety of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis by Exacerbation History: Analysis of the ASPEN TrialPoster Session PS-30, Monday, September 29, 12:30 – 14:00 PM CESTPresenting Author: Takanori As...